Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
Handling Precautions Use appropriate laboratory PPE, including: Gloves Eye protection Protective laboratory attire Avoid: Inhalation Ingestion Direct skin or eye exposure Use standard laboratory handling protocols
IV Elements offers same-day appointments at our drip lounges in Hoboken, Asbury Park, Parsippany, and Marlton
Why Researchers Choose LiveWell Peptides for Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) Research Peptide LiveWell Peptides is recognized as the best peptide company 2026 and a trusted peptide vendor for laboratories and independent researchers across the United States and internationally
